PSNL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 liep. 2024 @ 18:57):
Our systems believe the stock currently is overvalued by -0.02% compare to its pairs and should correct downwards.

Stats
Dzisiejszy wolumen	71 970
Średni wolumen	223 429
Kapitalizacja rynkowa	60.77M
EPS	$-0.260 ( Q1 \| 2024-05-08 )
Następna data zysków	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.620 (Sector) 42.63 (Industry) 0
ATR14	$0.00500 (0.43%)

ACRS 4.55%

AKU -17.87%

APDN 10.19%

BDSX -1.97%

BIOC 0.00%

BNGO -3.07%

BNR -3.02%

CDNA 0.13%

CEMI 0.22%

CHEK 0.51%

CNTG -4.49%

CSTL -1.75%

DMTK -11.32%

DRIO -5.04%

EXAS 0.86%

FLDM -7.02%

FLGT 1.07%

GENE -2.00%

GH -2.08%

GTH 0.12%

HTGM 0.00%

ICLR 1.15%

IDXX -2.37%

ILMN 2.13%

ISPC -1.78%

LAB -3.39%

LMDX 0.00%

MDXH -1.26%

ME -1.35%

MEDP -0.61%

MYGN -2.15%

MYNZ -17.06%

NDRA -5.56%

NEO 2.45%

NEOG -4.19%

NOTV -2.71%

NTRA -0.79%

OCDX 0.92%

OLK 0.06%

OPGN -3.10%

OPK -2.00%

PMD 3.31%

PRPO 7.19%

PSNL 0.00%

RDNT -1.83%

SERA 4.14%

SHC -2.49%

SQL 0.00%

STIM -1.72%

STRR -3.92%

STRRP -5.05%

SYNH 0.02%

TRIB -4.16%

TTOO 0.56%

TWST 2.86%

VIVO 0.00%

XGN -0.09%

Insider Trading

Date	Person	Action	Amount	type
2024-06-17	Chen Richard	Sell	5 055	Common Stock
2024-06-17	Tachibana Aaron	Sell	7 176	Common Stock
2024-06-17	Moore Stephen Michael	Sell	1 585	Common Stock
2024-05-17	Myers Woodrow A Jr	Buy	50 000	Stock Option (right to buy)
2024-05-17	Shoff Lonnie	Buy	50 000	Stock Option (right to buy)

INSIDER POWER
-59.51
Last 98 transactions
Buy: 4 067 705 \| Sell: 9 658 662

Korelacja (AI algo v.1.1b): Overvalued: -0.02% $1.170 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.07 (neutral)

Krótki: -0.47 (neutral)

Signal:(43.631) Neutral

Personalis Inc Korelacja

10 Najbardziej pozytywne korelacje
EXFY	0.819

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Personalis Inc Korelacja - Waluta/Towar

-0.27
( neutral )

0.00
( neutral )

-0.09
( neutral )

Personalis Inc Finanse

Annual	2023
Przychody:	$73.48M
Zysk brutto:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2023
Przychody:	$73.48M
Zysk brutto:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2022
Przychody:	$65.05M
Zysk brutto:	$13.35M (20.52 %)
EPS:	$-2.48

FY	2021
Przychody:	$85.49M
Zysk brutto:	$31.66M (37.03 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Personalis Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.